Autogenous Vaccine For Aquaculture Market

Global Market Study on Autogenous Vaccine for Aquaculture: Frequent Infectious Disease Outbreaks at Fish Farms Catalyzing Demand

Autogenous Vaccine for Aquaculture Market Segmented By Salmon, Tilapia, Bream, Labris Bergylta, Cyprinus Carpio, Sea Bass, Trout, Cylopterus Lumpus Fish Species with Bacteria, Virus Pathogen

  • January-2021
  • PMRREP32293
  • 194 Pages
  • Healthcare

About the Report

Autogenous vaccines are manufactured from specific pathogens, and isolates are taken from infected fish at fish farming facilities. However, despite increasing fish production and farming across the world, recurrent infectious disease is a major concern for the fish industry. Autogenous vaccines have been playing a vital role in bacterial disease control in aquaculture. It is the most effective method for preventing a wide range of bacterial and viral diseases. Moreover, leading veterinary pharmaceutical companies are improving their product portfolios and providing customized autogenous vaccine for particular pathogens. Leading key players are focusing on strengthening their product reach to fish farming companies across regions. Significant growth is expected to continue, as companies are focusing on enhancing the capacities of their manufacturing plants in various countries of the world. Adoption of autogenous vaccines for aquaculture is more in European countries, owing to changes in regulations.

In its new study, Persistence Market Research offers insights about key factors driving demand for autogenous vaccines for aquaculture. The report tracks global sales of autogenous vaccines for aquaculture in 20+ high-growth markets, along with analyzing the impact that COVID-19 has on the fish farming market in general, and autogenous vaccines in particular. The COVID-19 pandemic will have a negative impact on the industry, due to restrictions on transportation during the first few months in 2020.

Find Out More about the Report Coverage


  • IDT Biologika GmbH (Ridgeway Biologicals Ltd)
  • Ceva Biovac
  • Zoetis (PHARMAQAS)
  • Vaxxinova
  • Barramundi Asia Pte Ltd.(UVAXX Asia)
  • AniCon Labor GmbH
  • sanphar (ipeve)
  • Kennebec River Biosciences

Future Outlook Even Better than Previous Years

Rising incidence of disease outbreaks at fish farms and growth of fish production across the world are major factors increasing the need for autogenous vaccines for disease prevention. For instance, as per World Fish, due to frequent and severe disease outbreaks, the fish industry facing more than US$ 6 Bn loss annually. Moreover, in developing economies, fish disease frequently spreads between small-scale aquaculture farms due to water contamination. For preventing the spread of fish disease, strict guidelines and protocols are set by the World Organization for Animal Health (OIE). These guidelines provide preventive measures at the border, pre-border, and post-border stages with health certifications and quarantine checks. This market has been growing at around 4% over the past 5 years, but will see increasing growth over the next ten years through 2030, at around 5.5% CAGR.

Various autogenous vaccine manufacturers are focusing on increasing their production capacities to meet rising demand from fish farming companies. Expansion of production capacity by opening new plants for production of autogenous vaccines by key manufacturers is expected to propel market growth during the forecast period. For instance, in August 2017, DT Biologika and Gallant Custom Laboratories purchased a new facility in Canada that will significantly enhance the company’s vaccine development and manufacturing capabilities

Moreover, leading fish farming companies highly rely on autogenous vaccines during disease outbreaks, due to limited availability of commercial vaccines for fish diseases. Leading players are focusing on enhancing the capacities of their manufacturing plants in various countries of the world, due to strict regulations and bans on import and export of autogenous vaccines by some key countries.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Will Increasing Prevalence of Infectious Diseases Boost Demand for Autogenous Vaccines for Aquaculture?

Rising prevalence of infectious disease amongst fish species remains a global issue for fish farming. While infectious disease is a major risk to aquaculture production, underlying global epidemiological patterns are unknown. Infectious diseases are a restraining factor to expanding aquaculture production. Currently, emerging infectious diseases have caused industry-wide production losses in many geographical zones and species across the world. For instance, Vibriosis, Aeromonasis, Edwardsiellosis, Pseudomonasis, Streptococcosis, and Mycobacteriosis are the most common bacterial diseases in aquaculture. Some of these pathogens can be contact-zoonotic, and thus, good hygiene is crucial for aqua farmers, field technicians, and processors. For example, Mycobacterium marinum and Vibrio vulnificus Biotype 2 can cause contact zoonosis. Moreover, disease outbreaks increase production and treatment costs, which cause economic loss for fish production companies. Hence, this will increase demand for autogenous vaccines over the coming years.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

What is the Regulatory Impact on Autogenous Vaccines for Aquaculture?

As autogenous biologics are tailor-made vaccines that consist of antigens, they should be produced in a licensed facility. Moreover, regulations on the production of autogenous vaccines vary from country to country. Every country has its own regulations and license rules for the production of vaccines. Some countries have harmonized regulations for the use of fish autogenous vaccines, while others do not have regulations at all. For proper distribution of autogenous vaccines, it is required that countries state their regulations. As per regulatory guidelines, autogenous vaccines are produced under marketing authorization, and products must be evaluated by a certified veterinarian. Moreover, import and export of autogenous vaccine needs permits from both countries involved. In addition, some countries such as Australia provide licenses for only for permitted microorganisms. In japan, autogenous vaccines are prohibited. The Japanese government considers it as a bio-weapon. Thus, stringent regulations with lengthy license procedure times are likely to restrain progress of the autogenous vaccine for aquaculture industry.

Explore Persistence Market Research’s expertise in promulgation of the business !

Why are Manufacturing Activities Key to Market Consolidation?

The market is expanding in tandem with the growth of aquaculture farms. Frequent disease outbreaks at fish farms have resulted in slower growth and low production of fish, which causes heavy losses to fish farming companies. To overcome this problem, some fish farming companies have started in-house autogenous vaccine production. For instance, Barramundi Asia brings in-house autogenous vaccination solutions in collaboration with UVAXX Pte Ltd., which is an R&D institute for animal health and vaccines.

Moreover, as standard commercial vaccines are still not available for infectious diseases, and in some cases are ineffective to control the outbreak of diseases, leading players in the animal health industry such as CEVA BIOVAC, Zoetis, and HIPRA provide custom-made vaccines for fish farming.

To remain competitive and ensure a robust product pipeline, leading companies continue to identify potential assets from smaller firms that typically have limited resources to see projects through to the market. Through licensing deals and partnerships, companies acquire these new vaccines while continuing to pursue their in-house development strategies. For instance, in September 2020, Virbac announced the acquisition of the tilapia vaccine range of Ictyogroup. As such, Virbac will now be distributing and marketing both, registered and autogenous tilapia vaccines, globally.

What Is the Impact of Reduction in Antibiotic Usage on Global Sales?

Increasing prevalence of bacterial fish infections in farms leads to rising use of antibiotics, resulting in the presence of the same in the aquatic environment, which results in the spread of antibiotic-resistant bacteria. Antimicrobial resistance in fish species is one of the major issues faced in aquaculture, which is affecting the whole ecosystem. Hence, implementation of proper regulations and monitoring programmes is necessary to curb the dissemination of antimicrobial resistance in aquaculture. For instance, Aquaculture Stewardship Council Foundation standards make sure that fish farmers restrict the use of antibiotics, and monitor fish health and water quality. Moreover, they have banned the preventative use of antibiotics to stop the spread of antibiotic resistance.

Thus limitations on the use of antibiotics in aquaculture increase the adaption of autogenous vaccines amongst fish farming companies. In some countries such as Norway, Spanish autogenous vaccines are frequently used, and they have reduced the use of antibiotics.


Country-wise Insights

Why Does China have Lower Adoption Rates of Autogenous Vaccines for Aquaculture?

China is the largest fish producing region in the world, and contributes around 60% of global fish production. However, Chinese aquaculture industries depend on antibiotics for disease control. Some big fish farming companies have adopted vaccination to some extent.  Low adoption of autogenous vaccines is due to lack of awareness about vaccines and their benefits. Moreover, lack of production facilities and management to produce autogenous vaccines is one of the major factors hindering market growth. Chinese fish farming companies routinely use antibiotics for disease prevention due to their low cost. In recent years, the Chinese government has been tightening regulations on the use of antibiotics by fish farming companies. Thus, demand for autogenous vaccines will grow over the forecast period. As such, some key autogenous vaccine manufacturers are focusing on expansion in China. For instance, in April 2018, Pharmaq announced production of fish vaccines at a development center in Suzhou, China.

How will Growing Aquaculture Industry in the U.S Surge Demand for Autogenous Vaccines?

According to the United Nations Food and Agriculture Organization, in 2016, American marine aquaculture production was valued at more than US$ 400 million. Due to increasing demand for seafood, autogenous vaccines in the U.S. market have remarkable growth potential. These vaccines are projected to experience price growth as a result of excess demand for better treatment options for disease outbreaks. However, the autogenous vaccine industry’s ability to take advantage of this potential is currently limited because of stringent regulatory framework for the production of vaccines in USA.

Why is Production Capacity of Autogenous Vaccines Increasing in Brazil?

Various autogenous vaccine manufacturers are focusing on increasing their production capacities to meet rising demand from fish farming companies. Expansion of production capacity by opening new plants for the production of autogenous vaccine by key manufacturers is expected to propel market growth during the forecast period. For instance, in October 2019, SANPHAR SAÚDE ANIMAL acquired IPEVE, a Brazilian animal health company and a pioneer in autogenous vaccines.

How is Presence of Autogenous Vaccine Companies Benefitting Norway?

Norway will continue to be the leading country in fish production in Europe. Norway is expected show significant growth of autogenous vaccines for aquaculture, as the presence of autogenous vaccine companies in Norway is more. Some prominent players such as Zoetis and Vaxxinova are present in Norway, which creates notable revenue for the country. Moreover, large number of domestic players also available in Norway, which is creating a surge in autogenous vaccine production in the country. Moreover, adoption of autogenous vaccines amongst fish farming companies here is more than other countries of the European Union.

Category-wise Insights

What’s the Market Share of Fish Species in Producing Autogenous Vaccines?

According to Persistence Market Research, the salmon segment under fish species is expected to hold more than 40% of the market by the end of 2030. The segment will experience significant growth in countries such as Brazil, Mexico, Chile, and Canada. The tilapia segment will experience significant growth in the Asia Pacific region. Countries such as Singapore, Thailand, and Australia hold prominent market shares of tilapia by fish species.

Why Does Bacteria Hold a Mammoth 80% Share?

Bacteria, by pathogen type, holds more than 90% of the overall market share. Bacteria autogenous vaccines continue to account for increasing demand, due to easy approval for bacterial vaccines as compared to viral vaccines. Moreover, bacterial autogenous vaccines are allowed in all region of the world. However, production of viral autogenous vaccines is not allowed in countries such as Denmark, Finland, France, Iceland, Norway, Spain, and Sweden. As per Persistence Market Research analysis, Norway, Spain, and France hold significant shares in the autogenous vaccine for aquaculture market

Competitive Landscape

The global market is dominated by top manufacturers - Zoetis (PHARMAQ AS), HIPRA, Vaxxinova, and Barramundi Asia Pte Ltd. Major manufacturers are focusing on development of a wide range of autogenous vaccines for aquaculture. Moreover, these players focus on enhancing their global and regional presence through acquisitions and expansion.

  • For instance, in July 2019, Ceva Santé Animale announced the acquisition of IDT’s veterinary pharmaceutical and R&D activities.
  • In November 2016, Ceva announced the acquisition of Hertape Saude Animale Ltda. and Inova Biotecnologia Saude Animale Ltda., two leading Brazilian veterinary biopharmaceutical companies.
  • In April 2018, Pharmaq announced the production of fish vaccines at a development center in Suzhou, China.

Some of the leading companies operating in the market are:

  • IDT Biologika GmbH (Ridgeway Biologicals Ltd)
  • Ceva (Ceva Biovac)
  • "Zoetis (PHARMAQ
  • AS)"
  • Vaxxinova
  • Barramundi Asia Pte Ltd.(UVAXX Asia)
  • Virbac (ICTYO GROUP)
  • AniCon Labor GmbH
  • sanphar (ipeve)
  • AquaTactics Fish Health
  • Kennebec River Biosciences

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence available in the report.

Scope of Report



Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value and Units for Volume

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Brazil
  • Mexico
  • Peru
  • Chile
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Norway
  • Greece
  • Russia
  • China
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • South Africa

Key Segments Covered

  • Fish Species
  • Pathogen
  • End User
  • Region

Key Companies Profiled

  • IDT Biologika GmbH (Ridgeway Biologicals Ltd)
  • Ceva (Ceva Biovac)
  • "Zoetis (PHARMAQ
  • AS)"
  • Vaxxinova
  • Barramundi Asia Pte Ltd.(UVAXX Asia)
  • Virbac (ICTYO GROUP)
  • AniCon Labor GmbH
  • sanphar (ipeve)
  • AquaTactics Fish Health
  • Kennebec River Biosciences.

Report Coverage

  • Market Forecasts
  • Company Share Analysis
  • Competition Intelligence
  • DROT analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request


Autogenous Vaccine for Aquaculture Market by Category

Fish Species

    • Salmon
    • Tilapia
    • Bream
    • Labris Bergylta
    • Cyprinus Carpio
    • Sea Bass
    • Trout
    • Cylopterus Lumpus


  • Bacteria
  • Virus

End User

  • Aquatic Research Institute
  • Fish Farming Companies


  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA

Key Questions Answered in Report

Q1. Which is the most lucrative market for autogenous vaccines for aquaculture?

The U.S currently leads the global market for autogenous vaccines for aquaculture. The U.S will experience significant demand throughout the forecast period.

Q2. Which fish species is more prone to infectious?

Salmon fish farms have frequent disease outbreaks. Demand for autogenous vaccines is expected to remain high in the near future, especially due to higher production of salmon in North America and Europe.

Q3. Why are bacterial autogenous vaccines mostly used in aquaculture than viral autogenous vaccines?

In some countries, there are restrictions on the production of viral autogenous vaccines for aquaculture.

Q4. Which are some of the leading companies offering autogenous vaccines for aquaculture?

Some of the leading companies offering autogenous vaccines for aquaculture are Zoetis (PHARMAQ AS), HIPRA, Vaxxinova, Ceva Biovac., and Barramundi Asia Pte Ltd, among others.

Q5. Which disease-causing pathogen is driving sales of autogenous vaccines?

Vibriosis, Aeromonasis, Edwardsiellosis, Pseudomonasis, Streptococcosis, and Mycobacteriosis are the most common bacterial diseases in aquaculture. Rising prevalence of infectious diseases around the world is fuelling demand for autogenous vaccines in the aquaculture industry.

Enquiry before Buying

Is this research conducted by Persistence Market Research?

Yes, the research has been conducted by expert analysts of Persistence Market Research, through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Persistence Market Research?

Persistence Market Research follows a methodology that encompasses demand-side assessment of the market, and triangulates the same through supply-side analysis. This methodology is based on the use of standard market structure, methods and definitions. Request a detailed methodology.

Who are the respondents for primary research?

Persistence Market Research speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

What are the sources of secondary research?

Persistence Market Research conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request. 

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.

How can I buy this report?

Persistence Market Research provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.

Media Release


Osteoporosis Drugs Market

Global osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% with good revenue.

Progressive Multifocal Leukoencephalopathy Treatment Market

The global progressive multifocal leukoencephalopathy treatment market is projected to grow at a CAGR of 2.8% throughout the forecast period, Growing prevalence of HIV infection in several middles- and low-income economies is consequently expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period..

Dysphagia Management Market

Oropharyngeal dysphagia (od) has been the highly prevalent form of dysphagia, according to indications of research studies and surveys. However, greater prominence of od has been observed among the elderly patient population. While od remains among the most predominant precursors to the growth of the dysphagia management market,.

Immune Checkpoint Inhibitors Market

Expanding at a booming CAGR of 14.6%, the global market for immune checkpoint inhibitors market is expected to reach a value beyond US$ 35 Bn over 2018-2026..

Our Clients

Our Clients